Source: Health Products Regulatory Authority (IE) Revision Year: 2020 Publisher: Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
Bisolvon 4mg/5ml Oral Solution.
| Pharmaceutical Form |
|---|
|
Oral solution. A clear to almost clear, colourless to almost colourless solution with a fruity aromatic odour. |
Each 5 ml contains bromhexine hydrochloride 4 mg.
Excipients: contains maltitol liquid.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bromhexine |
Bromhexine is an expectorant used in the treatment of respiratory disorders associated with viscid or excessive mucus. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as “secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport”. |
| List of Excipients |
|---|
|
Maltitol liquid (E965) |
Bisolvon Oral Solution is available in amber type III glass bottles with tamper-evident polyethylene caps with low density polyethylene liners. The registered pack sizes are 100 ml, 200 ml, and 250 ml.
Not all pack sizes may be marketed.
A polypropylene measuring dish is provided.
Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
PA0540/180/001
Date of first authorisation: 14 November 1984
Date of last renewal: 01 April 2008
| Drug | Countries | |
|---|---|---|
| BISOLVON | Austria, Brazil, Germany, Ecuador, Finland, France, Croatia, Ireland, Japan, Malta, Mexico, Netherlands, New Zealand, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
